Clover Health Third Quarter 2026 Supplemental Q&A November 16, 2026 Ahead of our third quarter 2026 earnings call, we invited shareholders to submit…

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Regulation FD Disclosure. Clover Health (Nasdaq: CLOV) Third Quarter 2026 Supplemental Q&A November 16, 2026 Ahead of our third quarter 2026 earnings call, we invited shareholders to submit questions about Clover Health, our recent performance, and the outlook for our business. We appreciate the continued

Original reporting
Published Nov 16, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CLOV
Bullish
medium confidence
Mentioned
$CLOV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CLOVBullishLow
01

Why it matters

The disclosure reiterates a concrete Adjusted SG&A ratio improvement target for full-year 2026 and reiterates the company’s view that member maturation and operating leverage should improve economics through 2028, while declining to provide formal 2027 or 2028 guidance.

02

Market read

Traders get pre-earnings framing on cost-efficiency progress and the AI-driven care model, but the filing does not include new financial results or fresh guidance beyond the reiterated 2026 SG&A improvement target.

03

What to watch

The Q&A emphasizes AI and interoperability claims, but it provides limited measurable validation in this filing beyond previously published white-paper outcomes, leaving execution risk into 2027 growth.

Relevance 4/10Novelty 4/10Timing: ahead of the 3Q26 earnings call, filed Nov. 16, 2026

Background

Clover Health furnished a Regulation FD supplemental Q&A for shareholders ahead of its third quarter 2026 earnings call, addressing long-term scale, SG&A efficiency, and Counterpart Health AI and interoperability.

Company-level read

Ticker impact

$CLOVBullishMedium confidence
Context

Clover Health filed a Regulation FD supplemental Q&A outlining its 2026 cost-efficiency target and AI-driven care model economics through 2028.

Expected impact

Likely modest support for the stock as investors focus on the reiterated 2026 SG&A improvement target and the longer runway narrative through 2028.

Evidence & confidence

This is a Regulation FD Q&A ahead of the 3Q26 earnings call, reiterating a specific full-year 2026 Adjusted SG&A improvement target (100 to 150 bps) and describing operating leverage drivers, but it does not introduce new financial guidance numbers beyond that target.

Market effects

Reinforces the managed-care and AI-enabled care delivery narrative, potentially influencing sentiment toward AI-focused healthcare payers.

No clear regional spillover beyond US healthcare equities.

Limited, as the disclosure is company-specific and US-focused.

Counterpoint

Investors may discount the long-term earnings opportunity framing because the company explicitly avoids providing formal 2027 or 2028 guidance and relies on qualitative runway.

Key entities

  • Clover Health Investments Corp.

    Nasdaq-listed managed care company providing supplemental shareholder Q&A ahead of its 3Q26 earnings call.

  • Counterpart Health

    Clover’s AI-enabled platform referenced for clinical outcomes, provider efficiency, and interoperability capabilities.

  • Andrew Toy

    CEO quoted in the supplemental Q&A.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.